FibroGen, Inc. (FGEN) Earnings History
Annual and quarterly earnings data from 2012 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 47.5% | -507.8% | -160.6% |
| 2023 | 91.5% | -689.5% | -607.3% |
| 2022 | 85.6% | -213.9% | -208.7% |
| 2021 | -90.9% | -122.6% | -123.3% |
| 2020 | 95.0% | -108.8% | -107.4% |
Download Data
Export FGEN earnings history in CSV or JSON format
Free sign-in required to download data
FibroGen, Inc. (FGEN) Earnings Overview
As of March 1, 2026, FibroGen, Inc. (FGEN) reported trailing twelve-month net income of $216M, reflecting +0.8% year-over-year growth. The company earned $53.33 per diluted share over the past four quarters, with a net profit margin of -1.6%.
Looking at the long-term picture, FGEN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$15M in fiscal 2013.
FibroGen, Inc. maintains positive profitability with a gross margin of 0.5%, operating margin of -5.1%, and net margin of -1.6%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including ARGX ($923M net income, 0.4% margin), CANF (-$9M net income, -11.7% margin), AKTX (-$16M net income), FGEN has room to improve margins relative to the peer group. Compare FGEN vs ARGX →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
13 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | -$48M | +83.3% | -$150M | $-0.48 | -160.6% | -507.8% |
| 2023 | -$284M | +3.2% | -$323M | $-2.92 | -607.3% | -689.5% |
| 2022 | -$294M | -1.3% | -$301M | $-3.15 | -208.7% | -213.9% |
| 2021 | -$290M | -53.2% | -$289M | $-3.15 | -123.3% | -122.6% |
| 2020 | -$189M | -145.9% | -$192M | $-2.11 | -107.4% | -108.8% |
| 2019 | -$77M | +10.9% | -$89M | $-0.89 | -30.0% | -34.8% |
| 2018 | -$86M | +31.5% | -$87M | $-1.03 | -40.6% | -40.7% |
| 2017 | -$126M | -104.6% | -$123M | $-1.73 | -100.4% | -97.6% |
| 2016 | -$62M | +28.1% | -$54M | $-0.98 | -34.3% | -29.9% |
| 2015 | -$86M | -44.2% | -$78M | $-1.42 | -47.4% | -42.9% |
See FGEN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FGEN Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare FGEN vs AGIO
See how FGEN stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is FGEN growing earnings?
FGEN EPS of $53.33 reflects slowing growth at +0.8%, below the 5-year CAGR of N/A. TTM net income is $216M. Expansion rate has moderated.
What are FGEN's profit margins?
FibroGen, Inc. net margin is -1.6%, with operating margin at -5.1%. Below-average margins reflect competitive or cost pressures.
How consistent are FGEN's earnings?
FGEN earnings data spans 2012-2024. The current earnings trend is +0.8% YoY. Historical data enables comparison across business cycles.